Last reviewed · How we verify
modified PENTOCLO (mPENTOCLO)
Modified PENTOCLO is a pentamidine-based compound designed to enhance antimicrobial or antiparasitic activity through structural optimization.
Modified PENTOCLO is a pentamidine-based compound designed to enhance antimicrobial or antiparasitic activity through structural optimization. Used for Pneumocystis jirovecii pneumonia (PCP) prophylaxis or treatment (presumed based on pentamidine parent compound).
At a glance
| Generic name | modified PENTOCLO (mPENTOCLO) |
|---|---|
| Also known as | PENtoxyphylline, TOcopherol, and CLOdronate |
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
PENTOCLO (pentamidine) is traditionally used against protozoal infections such as Pneumocystis jirovecii pneumonia and leishmaniasis. The modified version (mPENTOCLO) likely incorporates chemical or formulation changes to improve bioavailability, reduce toxicity, or enhance efficacy against target pathogens. The exact modifications and mechanism require access to Sunnybrook's proprietary development data.
Approved indications
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis or treatment (presumed based on pentamidine parent compound)
Common side effects
- Nephrotoxicity
- Hypoglycemia
- Hypotension
- Pancreatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- modified PENTOCLO (mPENTOCLO) CI brief — competitive landscape report
- modified PENTOCLO (mPENTOCLO) updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI